Contents

Contributors xiii

1. Physiology of erythropoiesis 1
   U. Testa

2. Biology of EPO and EPO-receptor 67
   C. Lacombe and P. Mayeux

3. The role of erythropoietin receptor expression on tumor cells 81
   J. Fandrey

4. Problems associated with erythropoietin receptor determination on tumor cells 103
   A. Österborg

5. Definition, classification and characterization of anemia in cancer 117
   M. R. Nowrousian

6. Pathophysiology of anemia in cancer 149
   M. R. Nowrousian

7. Prevalence and incidence of anemia and risk factors for anemia in patients with cancer 189
   H. Ludwig

8. Significance of anemia in cancer chemotherapy 207
   M. R. Nowrousian

9. Incidence and impact of anemia in radiation oncology 249
   J. Dunst and M. Molls

10. Relationship between hemoglobin levels and tumor oxygenation 265
    P. Vaupel, A. Mayer and M. Höckel
11. Tumor hypoxia and therapeutic resistance  
   P. Vaupel and M. Höckel  
   283

12. Symptoms of anemia  
   R. Pirker  
   307

13. Impact of anemia and red blood cell transfusion on organ function  
   M. R. Nowrousian  
   317

14. Relationship of hemoglobin, fatigue, and quality of life in anemic cancer patients  
   Z. Butt and D. Cella  
   369

15. When to use red blood cell transfusions in cancer patients with solid tumours?  
   J. K. Jacob and P. J. Barrett-Lee  
   393

16. Pharmacology, pharmacokinetics and safety of recombinant human erythropoietin preparations  
   W. Jelkmann  
   407

17. Epoetin treatment of anemia associated with multiple myeloma and non-Hodgkin’s lymphoma  
   A. Österborg  
   433

18. rhEPO in anemic patients with solid tumors and chemotherapy – efficacy and safety  
   M. R. Nowrousian  
   449

19. Early intervention with recombinant human erythropoietin for chemotherapy-induced anemia  
   G. H. Lyman and J. Glaspy  
   509

20. Recombinant human erythropoietin (rhEPO) therapy in myelodysplasia  
   E. Hellström-Lindberg  
   531

21. Prediction of response to rhEPO in the anemia of cancer  
   Y. Beguin and G. Van Straelen  
   541

22. rhEPO in hematopoietic stem cell transplantation  
   G. Van Straelen and Y. Beguin  
   583
Contents

23. Treatment of anemia with rhEPO in radiation oncology 615
   J. Dunst

24. Recombinant human erythropoietin in pediatric oncology 635
   C. Hastings and J. Feusner

25. rhEPO in surgical oncology 663
   M. J. Fontaine and L. T. Goodnough

26. Erythropoiesis, iron metabolism and iron supplementation during erythropoietin therapy 679
   L. T. Goodnough

27. Are there risks for use of iron in cancer patients? 703
   P. Gascón

28. Metabolic and physiologic effects of rhEPO in anemic cancer patients 713
   K. Lundholm and P. Daneryd

29. Effects of rhEPO on quality of life in anemic cancer patients 729
   S. Chowdhury, J. F. Spicer, and P. G. Harper

30. Thrombosis during therapy with erythropoiesis stimulating agents in cancer 745
   J. Glaspy

31. The effect of rhEPO on survival in anemic cancer patients 759
   T. J. Littlewood

32. From bench to bedside: Neuroprotective effects of erythropoietin 771
   H. Ehrenreich and C. Bartels

33. rhEPO in patients with anemia and congestive heart failure 793
   D. S. Silverberg, D. Wexler, A. Iaina, S. Steinbruch, Y. Wollman, and D. Schwartz

34. Cost-effectiveness of treating cancer anaemia 813
   P. Cornes

Addendum 851

Index 853
Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology
Scientific and Clinical Aspects of Anemia in Cancer
Nowrousian, M.R. (Ed.)
2008, XVIII, 866 p., Hardcover
ISBN: 978-3-211-25223-9